Reference
Rupp T, et al. Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints. JAMA Internal Medicine : 29 Nov 2016. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2016.7761
Rights and permissions
About this article
Cite this article
Costs of cancer drugs in US not based on QOL benefit. PharmacoEcon Outcomes News 768, 14 (2016). https://doi.org/10.1007/s40274-016-3612-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3612-1